Dr. Chang の 血液腫瘤筆記本

Study

Setting

Chemotherapy backbone

Bevacizumab dose

PFS

OS

GOG-0218

Front line

Carboplatin AUC 6

Paclitaxel 175mg/m2

Q3W

15 mg/kg Q3W

Maintenance (15M)

14.1M vs. 10.3M

HR 0.717

P < 0.0001

39.7M vs. 39.3M

HR 0.915

P = 0.252

ICON-7

Front line

Carboplatin AUC 6

Paclitaxel 175mg/m2

Q3W

7.5 mg/kg Q3W

Maintenance (12M)

19.8M vs. 17.4M

HR 0.87

P = 0.039

58.6M vs. 58.0M

HR 0.99

P = 0.85

OCEANS

Recurrent

Platinum-S

Carboplatin AUC 4

Gemcitabine 1000mg/m2, D1&8

Q3W

15 mg/kg Q3W

Treatment until PD or Toxicity

12.4M vs. 8.4M

HR 0.484

P < 0.0001

33.3M vs. 35.2M

HR 1.027

AURELIA

Recurrent

Platinum-R

1. 1.      Weekly Paclitaxel
2. 2.      Weekly Topotecan
3. 3.      Liposomal doxorubicin QM

15 mg/kg Q3W

Treatment until PD or Toxicity

6.7M vs. 3.4M

HR 0.48

P < 0.001

16.6M vs. 13.3M

HR 0.85

P = 0.174

GOG-0213

(2015 SGO)

Recurrent

Platinum-S

Carboplatin AUC 5

Paclitaxel 175mg/m2

Q3W

15 mg/kg Q3W

Treatment until PD or Toxicity

13.8M vs. 10.4M

HR 0.614

P < 0.0001

42.2M vs. 37.3M

HR 0.827

P = 0.056